Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Bicycle Therapeutics (BCYC – Research Report) on April 10. The company’s shares closed last Monday at $28.81, close to its 52-week low of $26.39.
According to TipRanks.com, Chang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.2% and a 25.0% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Mersana Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bicycle Therapeutics with a $71.14 average price target, representing a 124.6% upside. In a report issued on April 7, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $80.00 price target.
The company has a one-year high of $62.08 and a one-year low of $26.39. Currently, Bicycle Therapeutics has an average volume of 289K.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCYC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More on BCYC:
- Robert W. Baird Remains a Hold on Bed Bath & Beyond (BBBY)
- Leerink Partners Believes R1 RCM (RCM) Still Has Room to Grow
- Wall Street Analysts Are Bullish on Top Industrial Goods Picks
- Analysts Are Bullish on Top Healthcare Stocks: Genocea Biosciences (GNCA), Blueprint Medicines (BPMC)
- Evercore ISI Sticks to Its Buy Rating for CBRE Group (CBRE)